The present invention relates to an immunogenic polypeptide, a nucleic acid encoding the same, a pharmaceutical composition comprising the same and the immunogenic polypeptide, nucleic acid or pharmaceutical composition for use as a medicament, particularly a vaccine, or for use in a method of treating or preventing a Borrelia infection.
C07K 14/20 - Peptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés provenant de bactéries provenant de Spirochaetales (O), p. ex. Tréponème, Leptospira
A61K 39/00 - Préparations médicinales contenant des antigènes ou des anticorps
A61K 39/39 - Préparations médicinales contenant des antigènes ou des anticorps caractérisées par les additifs immunostimulants, p. ex. par les adjuvants chimiques
A61K 39/00 - Préparations médicinales contenant des antigènes ou des anticorps
A61K 39/39 - Préparations médicinales contenant des antigènes ou des anticorps caractérisées par les additifs immunostimulants, p. ex. par les adjuvants chimiques
A61P 31/14 - Antiviraux pour le traitement des virus ARN
C07K 14/18 - Togaviridae, p. ex. flavivirus, virus de la peste, virus de la fièvre jaune, virus de l'hépatite C, virus de l'encéphalite japonaise
C12N 7/00 - Virus, p. ex. bactériophagesCompositions les contenantLeur préparation ou purification
The present invention relates to a vaccine for the prevention or treatment of a Chikungunya virus infection in immunocompromised or immunosuppressed subjects.
A61K 9/00 - Préparations médicinales caractérisées par un aspect particulier
A61K 39/00 - Préparations médicinales contenant des antigènes ou des anticorps
A61K 39/39 - Préparations médicinales contenant des antigènes ou des anticorps caractérisées par les additifs immunostimulants, p. ex. par les adjuvants chimiques
A61P 31/14 - Antiviraux pour le traitement des virus ARN
C07K 14/18 - Togaviridae, p. ex. flavivirus, virus de la peste, virus de la fièvre jaune, virus de l'hépatite C, virus de l'encéphalite japonaise
C12N 7/00 - Virus, p. ex. bactériophagesCompositions les contenantLeur préparation ou purification
The present invention relates to method of producing a lipidated protein, a pharmaceutical composition comprising the protein of any of SEQ ID NOs: 1, 2, and/or 3 and/or the lipidated form of a protein comprising the protein of SEQ ID NO: 7 (C-TAB.G5) and/or SEQ ID NO: 8 (C-TAB.G5.1), especially the protein of SEQ ID NO: 12 (Lip-C-TAB.G5.1), and/or a lipidated form of a protein comprising the protein of SEQ ID NO: 15 (Spike protein of SARS-CoV-2) and/or a lipidated form of a protein comprising the any of the proteins of SEQ ID NOs: 16-22 (hMPV F protein), and the pharmaceutical composition for use as a medicament, particularly a vaccine and/or for use in a method for eliciting an immune response in a human against Lyme disease, a disease caused by Clostridium difficile or hMPV and/or of SARS-CoV-2 (COVID-19).
C12P 21/02 - Préparation de peptides ou de protéines comportant une séquence connue de plusieurs amino-acides, p. ex. glutathion
C07K 1/107 - Procédés généraux de préparation de peptides par modification chimique de peptides précurseurs
C07K 14/33 - Peptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés provenant de bactéries provenant de Clostridium (G)
C07K 14/005 - Peptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés provenant de virus
The present invention relates to an aluminum composition for use as an adjuvant or for use in a method of vaccination, the use of an alum-adjuvanted vaccine composition comprising less than 1.25 ppb copper for increasing bioavailability of an antigen in the vaccine, wherein the antigen is a protein, particularly an OspA protein or a Clostridium difficile toxin A and toxin B fusion protein or a SARS-CoV-2 protein or an hMPV protein, in an aluminum-containing vaccine composition and the use of a radical quenching compound such as L-methionine for increasing bioavailability of a protein antigen in a copper- and aluminum-containing vaccine composition.
A61K 39/39 - Préparations médicinales contenant des antigènes ou des anticorps caractérisées par les additifs immunostimulants, p. ex. par les adjuvants chimiques
A61K 47/20 - Composés organiques, p. ex. hydrocarbures naturels ou synthétiques, polyoléfines, huile minérale, gelée de pétrole ou ozocérite contenant du soufre, p. ex. sulfoxyde de diméthyle [DMSO], docusate, laurylsulfate de sodium ou acides aminosulfoniques
The present invention relates to a lipidated immunogenic Clostridium difficile toxin A and toxin B polypeptide, a pharmaceutical composition comprising the immunogenic Clostridium difficile toxin A and/or toxin B polypeptide for use as a medicament, particularly a vaccine and/or for use in a method for the prevention or treatment of C. difficile infection and/or C. difficile-associated disease.
C07K 14/33 - Peptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés provenant de bactéries provenant de Clostridium (G)
The present invention relates to compositions and methods for the prevention and treatment of Borrelia infection. Particularly, the present invention relates to a polypeptide comprising a hybrid C-terminal fragment of an outer surface protein A (OspA), a nucleic acid coding the same, an antibody specifically binding the same, a pharmaceutical composition (particularly for use as a medicament or in a method of treating or preventing a Borrelia infection) comprising the polypeptide and/or the nucleic acid and/or the antibody, a method of treating or preventing a Borrelia infection and a method of immunizing a subject.
C07K 14/20 - Peptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés provenant de bactéries provenant de Spirochaetales (O), p. ex. Tréponème, Leptospira
C07K 16/12 - Immunoglobulines, p. ex. anticorps monoclonaux ou polyclonaux contre du matériel provenant de bactéries
A61K 39/39 - Préparations médicinales contenant des antigènes ou des anticorps caractérisées par les additifs immunostimulants, p. ex. par les adjuvants chimiques
22.
MUTANT FRAGMENTS OF OSPA AND METHODS AND USES RELATING THERETO
The present invention relates to a polypeptide comprising a mutant fragment of an outer surface protein A (OspA), a nucleic acid coding the same, a pharmaceutical composition (particularly for use as a medicament of in a method of treating or preventing a Borrelia infection) comprising the polypeptide and/or the nucleic acid, a method of treating or preventing a Borrelia infection and a method of immunizing a subject.
C07K 14/20 - Peptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés provenant de bactéries provenant de Spirochaetales (O), p. ex. Tréponème, Leptospira
C07K 16/12 - Immunoglobulines, p. ex. anticorps monoclonaux ou polyclonaux contre du matériel provenant de bactéries
C12P 21/02 - Préparation de peptides ou de protéines comportant une séquence connue de plusieurs amino-acides, p. ex. glutathion
A61K 9/00 - Préparations médicinales caractérisées par un aspect particulier
A61K 39/00 - Préparations médicinales contenant des antigènes ou des anticorps
A61K 39/39 - Préparations médicinales contenant des antigènes ou des anticorps caractérisées par les additifs immunostimulants, p. ex. par les adjuvants chimiques
A61P 31/14 - Antiviraux pour le traitement des virus ARN
C07K 14/18 - Togaviridae, p. ex. flavivirus, virus de la peste, virus de la fièvre jaune, virus de l'hépatite C, virus de l'encéphalite japonaise
C12N 7/00 - Virus, p. ex. bactériophagesCompositions les contenantLeur préparation ou purification
The present invention relates to a composition comprising the OspA fusion protein of SEQ ID NO: 1 (LipSID1-S2D1), the OspA fusion protein of SEQ ID NO: 2 (Lip-S4D1-SShybD1) and the OspA fusion protein of SEQ ID NO: 3 (Lip-S5D1-S6D1) for use in a vaccine or for use in a method for eliciting an immune response in a human against Lyme disease.
This present invention provides C-TAB.G5 and C-TAB.G5.1 isolated polypeptides comprising the receptor binding domains of C. difficile toxin A and toxin B as set forth in the amino acid sequences of SEQ ID NO: 2 and SEQ ID NO: 4. The C-TAB.G5 and C-TAB.G5.1 isolated polypeptides may be used to neutralize toxic effects of C. difficile toxin A and/or toxin B.
A61K 39/08 - Clostridium, p. ex. Clostridium tetani
C07K 14/33 - Peptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés provenant de bactéries provenant de Clostridium (G)
C07K 16/12 - Immunoglobulines, p. ex. anticorps monoclonaux ou polyclonaux contre du matériel provenant de bactéries
27.
Multivalent OspA polypeptides and methods and uses relating thereto
A61K 39/39 - Préparations médicinales contenant des antigènes ou des anticorps caractérisées par les additifs immunostimulants, p. ex. par les adjuvants chimiques
C07K 14/20 - Peptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés provenant de bactéries provenant de Spirochaetales (O), p. ex. Tréponème, Leptospira
A61K 39/00 - Préparations médicinales contenant des antigènes ou des anticorps
The present disclosure relates to immunogenic compositions comprising a severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) antigen, and a toll-like receptor 9 (TLR9) agonist, such as an oligonucleotide comprising an unmethylated cytidine-phospho-guano sine (CpG) motif. The immunogenic compositions are suitable for stimulating an immune response against a SARS-CoV-2 in an individual in need thereof.
Described herein are CpG-adjuvanted SARS-CoV-2 vaccines and compositions and methods of producing and administering said vaccines to subjects in need thereof.
A61K 9/00 - Préparations médicinales caractérisées par un aspect particulier
A61K 39/00 - Préparations médicinales contenant des antigènes ou des anticorps
A61K 39/39 - Préparations médicinales contenant des antigènes ou des anticorps caractérisées par les additifs immunostimulants, p. ex. par les adjuvants chimiques
A61P 31/14 - Antiviraux pour le traitement des virus ARN
C07K 14/18 - Togaviridae, p. ex. flavivirus, virus de la peste, virus de la fièvre jaune, virus de l'hépatite C, virus de l'encéphalite japonaise
C12N 7/00 - Virus, p. ex. bactériophagesCompositions les contenantLeur préparation ou purification
05 - Produits pharmaceutiques, vétérinaires et hygièniques
Produits et services
Pharmaceutical preparations for human and veterinary use for the treatment of autoimmune diseases, inflammation, infectious diseases; vaccines for human use
34.
Mutant fragments of OspA and methods and uses relating thereto
C07K 14/20 - Peptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés provenant de bactéries provenant de Spirochaetales (O), p. ex. Tréponème, Leptospira
The invention relates to means and methods for preparing aqueous composition comprising aluminium and a protein said composition comprising less than 700 ppm heavy metal on the basis of weight with respect to the aluminium content. The invention further relates to aqueous compositions comprising a protein and an aluminium-salt, said composition comprising less than 350 ppb heavy metal based on the weight of the aqueous composition.
A61K 39/39 - Préparations médicinales contenant des antigènes ou des anticorps caractérisées par les additifs immunostimulants, p. ex. par les adjuvants chimiques
A61K 38/16 - Peptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés
C07K 14/00 - Peptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés
A61K 39/08 - Clostridium, p. ex. Clostridium tetani
C07K 14/33 - Peptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés provenant de bactéries provenant de Clostridium (G)
C07K 16/12 - Immunoglobulines, p. ex. anticorps monoclonaux ou polyclonaux contre du matériel provenant de bactéries
A61K 39/00 - Préparations médicinales contenant des antigènes ou des anticorps
05 - Produits pharmaceutiques, vétérinaires et hygièniques
Produits et services
(1) Pharmaceutical preparations for human and veterinary use for the treatment of autoimmune diseases, inflammation, infectious diseases, namely, Chikungunya disease; vaccines for human use
The present invention relates to an aluminum composition for use as an adjuvant or for use in a method of vaccination, the use of an alum-adjuvanted vaccine composition comprising less than 1.25 ppb copper for increasing bioavailability of an antigen in the vaccine, wherein the antigen is a protein, particularly an OspA protein or a Clostridium difficile toxin A and toxin B fusion protein or a SARS-CoV-2 protein or an hMPV protein, in an aluminum-containing vaccine composition and the use of a radical quenching compound such as L- methionine for increasing bioavailability of a protein antigen in a copper- and aluminum-containing vaccine composition.10
C12P 21/02 - Préparation de peptides ou de protéines comportant une séquence connue de plusieurs amino-acides, p. ex. glutathion
C12P 7/64 - GraissesHuilesCires de type esterAcides gras supérieurs, c.-à-d. ayant une chaîne continue d'au moins sept atomes de carbone liée à un groupe carboxyleHuiles ou graisses oxydées
C07K 14/33 - Peptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés provenant de bactéries provenant de Clostridium (G)
C07K 14/165 - Coronaviridae, p. ex. virus de la bronchite infectieuse aviaire
C07K 14/115 - Paramyxoviridae, p. ex. virus para-influenza
C07K 14/20 - Peptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés provenant de bactéries provenant de Spirochaetales (O), p. ex. Tréponème, Leptospira
The present invention relates to a composition comprising the OspA fusion protein of SEQ ID NO: 1 (LipSlDl-S2Dl), the OspA fusion protein of SEQ ID NO: 2 (Lip-S4D1- SShybD1) and the OspA fusion protein of SEQ ID NO: 3 (Lip-S5D1-S6D1) for use in a vaccine or for use in a method for eliciting an immune response in a human against Lyme disease.
C07K 14/20 - Peptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés provenant de bactéries provenant de Spirochaetales (O), p. ex. Tréponème, Leptospira
The present invention relates to method of producing a lipidated protein, a pharmaceutical composition comprising the protein of any of SEQ ID NOs: 1, 2, and/or 3 and/or the lipidated form of a protein comprising the protein of SEQ ID NO: 7 (C-TAB.G5) and/or SEQ ID NO: 8 (C-TAB.G5.1), especially the protein of SEQ ID NO: 12 (Lip-C- TAB.G5.1), and/or a lipidated form of a protein comprising the protein of SEQ ID NO: 15 (Spike protein of SARS-CoV-2) and/or a lipidated form of a protein comprising the any of the proteins of SEQ ID NOs: 16-22 (hMPV F protein), and the pharmaceutical composition for use as a medicament, particularly a vaccine and/or for use in a method for eliciting an immune response in a human against Lyme disease, a disease caused by Clostridium difficile or hMPV and/or of SARS-CoV-2 (COVID-19).
A61K 39/08 - Clostridium, p. ex. Clostridium tetani
A61K 39/155 - Paramyxoviridae, p. ex. virus de para-influenza
A61K 39/215 - Coronaviridae, p. ex. virus de la bronchite infectieuse aviaire
C07K 14/115 - Paramyxoviridae, p. ex. virus para-influenza
C07K 14/165 - Coronaviridae, p. ex. virus de la bronchite infectieuse aviaire
C07K 14/20 - Peptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés provenant de bactéries provenant de Spirochaetales (O), p. ex. Tréponème, Leptospira
C07K 14/33 - Peptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés provenant de bactéries provenant de Clostridium (G)
C12P 7/64 - GraissesHuilesCires de type esterAcides gras supérieurs, c.-à-d. ayant une chaîne continue d'au moins sept atomes de carbone liée à un groupe carboxyleHuiles ou graisses oxydées
C12P 21/02 - Préparation de peptides ou de protéines comportant une séquence connue de plusieurs amino-acides, p. ex. glutathion
50.
COMPOSITIONS COMPRISING THREE OSPA FUSION PROTEINS FOR MEDICAL USE
The present invention relates to a composition comprising the OspA fusion protein of SEQ ID NO: 1 (LipSlDl-S2Dl), the OspA fusion protein of SEQ ID NO: 2 (Lip-S4D1- SShybD1) and the OspA fusion protein of SEQ ID NO: 3 (Lip-S5D1-S6D1) for use in a vaccine or for use in a method for eliciting an immune response in a human against Lyme disease.
C07K 14/20 - Peptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés provenant de bactéries provenant de Spirochaetales (O), p. ex. Tréponème, Leptospira
Clostridium difficileClostridium difficile toxin A and toxin B fusion protein or a SARS-CoV-2 protein or an hMPV protein, in an aluminum-containing vaccine composition and the use of a radical quenching compound such as L- methionine for increasing bioavailability of a protein antigen in a copper- and aluminum-containing vaccine composition.10
Described herein are CpG-adjuvanted SARS-CoV-2 vaccines and compositions and methods of producing and administering said vaccines to subjects in need thereof.
Described herein are CpG-adjuvanted SARS-CoV-2 vaccines and compositions and methods of producing and administering said vaccines to subjects in need thereof.
C12P 21/04 - Peptides ou polypeptides cycliques ou pontés, p. ex. bacitracine
A61K 39/08 - Clostridium, p. ex. Clostridium tetani
C07K 14/33 - Peptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés provenant de bactéries provenant de Clostridium (G)
C07K 16/12 - Immunoglobulines, p. ex. anticorps monoclonaux ou polyclonaux contre du matériel provenant de bactéries
A61K 39/00 - Préparations médicinales contenant des antigènes ou des anticorps
A61P 31/14 - Antiviraux pour le traitement des virus ARN
C07K 14/18 - Togaviridae, p. ex. flavivirus, virus de la peste, virus de la fièvre jaune, virus de l'hépatite C, virus de l'encéphalite japonaise
C12N 7/06 - Inactivation ou atténuationProduction de parties élémentaires de virus par traitement chimique
A61K 39/39 - Préparations médicinales contenant des antigènes ou des anticorps caractérisées par les additifs immunostimulants, p. ex. par les adjuvants chimiques
C12N 7/00 - Virus, p. ex. bactériophagesCompositions les contenantLeur préparation ou purification
A61L 2/00 - Procédés ou appareils de désinfection ou de stérilisation de matériaux ou d'objets autres que les denrées alimentaires ou les lentilles de contactAccessoires à cet effet
58.
Mutant fragments of OspA and methods and uses relating thereto
A61K 39/39 - Préparations médicinales contenant des antigènes ou des anticorps caractérisées par les additifs immunostimulants, p. ex. par les adjuvants chimiques
C07K 14/20 - Peptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés provenant de bactéries provenant de Spirochaetales (O), p. ex. Tréponème, Leptospira
C12N 7/00 - Virus, p. ex. bactériophagesCompositions les contenantLeur préparation ou purification
A61K 39/39 - Préparations médicinales contenant des antigènes ou des anticorps caractérisées par les additifs immunostimulants, p. ex. par les adjuvants chimiques
A61K 9/00 - Préparations médicinales caractérisées par un aspect particulier
A61P 31/14 - Antiviraux pour le traitement des virus ARN
C07K 14/18 - Togaviridae, p. ex. flavivirus, virus de la peste, virus de la fièvre jaune, virus de l'hépatite C, virus de l'encéphalite japonaise
The invention relates to means and methods for preparing aqueous composition comprising aluminium and a protein said composition comprising less than 700 ppm heavy metal on the basis of weight with respect to the aluminium content. The invention further relates to aqueous compositions comprising a protein and an aluminium-salt, said composition comprising less than 350 ppb heavy metal based on the weight of the aqueous composition.
A61K 39/395 - AnticorpsImmunoglobulinesImmunsérum, p. ex. sérum antilymphocitaire
A61K 39/39 - Préparations médicinales contenant des antigènes ou des anticorps caractérisées par les additifs immunostimulants, p. ex. par les adjuvants chimiques
A61K 38/16 - Peptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés
C07K 14/20 - Peptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés provenant de bactéries provenant de Spirochaetales (O), p. ex. Tréponème, Leptospira
C07K 16/12 - Immunoglobulines, p. ex. anticorps monoclonaux ou polyclonaux contre du matériel provenant de bactéries
C12P 21/02 - Préparation de peptides ou de protéines comportant une séquence connue de plusieurs amino-acides, p. ex. glutathion
A61K 39/39 - Préparations médicinales contenant des antigènes ou des anticorps caractérisées par les additifs immunostimulants, p. ex. par les adjuvants chimiques
A61K 48/00 - Préparations médicinales contenant du matériel génétique qui est introduit dans des cellules du corps vivant pour traiter des maladies génétiquesThérapie génique
A61K 9/00 - Préparations médicinales caractérisées par un aspect particulier
A61P 31/14 - Antiviraux pour le traitement des virus ARN
C07K 14/18 - Togaviridae, p. ex. flavivirus, virus de la peste, virus de la fièvre jaune, virus de l'hépatite C, virus de l'encéphalite japonaise
A61K 39/00 - Préparations médicinales contenant des antigènes ou des anticorps
A61K 39/08 - Clostridium, p. ex. Clostridium tetani
C07K 14/33 - Peptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés provenant de bactéries provenant de Clostridium (G)
C07K 16/12 - Immunoglobulines, p. ex. anticorps monoclonaux ou polyclonaux contre du matériel provenant de bactéries
Described herein are improved purification methods for Zika virus vaccines and compositions. Also described are Zika vaccines and methods of producing and administering said Zika vaccines to subjects in need thereof.
C12N 7/06 - Inactivation ou atténuationProduction de parties élémentaires de virus par traitement chimique
C07K 14/18 - Togaviridae, p. ex. flavivirus, virus de la peste, virus de la fièvre jaune, virus de l'hépatite C, virus de l'encéphalite japonaise
C12N 7/00 - Virus, p. ex. bactériophagesCompositions les contenantLeur préparation ou purification
A61K 39/39 - Préparations médicinales contenant des antigènes ou des anticorps caractérisées par les additifs immunostimulants, p. ex. par les adjuvants chimiques
A61K 39/00 - Préparations médicinales contenant des antigènes ou des anticorps
67.
Mutant fragments of OspA and methods and uses relating thereto
C07K 14/20 - Peptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés provenant de bactéries provenant de Spirochaetales (O), p. ex. Tréponème, Leptospira
C07K 16/12 - Immunoglobulines, p. ex. anticorps monoclonaux ou polyclonaux contre du matériel provenant de bactéries
A61K 39/39 - Préparations médicinales contenant des antigènes ou des anticorps caractérisées par les additifs immunostimulants, p. ex. par les adjuvants chimiques
A61K 39/00 - Préparations médicinales contenant des antigènes ou des anticorps
A61P 31/14 - Antiviraux pour le traitement des virus ARN
C12N 7/06 - Inactivation ou atténuationProduction de parties élémentaires de virus par traitement chimique
C12N 7/00 - Virus, p. ex. bactériophagesCompositions les contenantLeur préparation ou purification
A61K 39/39 - Préparations médicinales contenant des antigènes ou des anticorps caractérisées par les additifs immunostimulants, p. ex. par les adjuvants chimiques
A61K 39/00 - Préparations médicinales contenant des antigènes ou des anticorps
69.
MULTIVALENT OSPA POLYPEPTIDES AND METHODS AND USES RELATING THERETO
The present invention relates to an immunogenic polypeptide, a nucleic acid encoding the same, a pharmaceutical composition comprising the same and the immunogenic polypeptide, nucleic acid or pharmaceutical composition for use as a medicament, particularly a vaccine, or for use in a method of treating or preventing a Borrelia infection.
C07K 14/20 - Peptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés provenant de bactéries provenant de Spirochaetales (O), p. ex. Tréponème, Leptospira
70.
MULTIVALENT OSPA POLYPEPTIDES AND METHODS AND USES RELATING THERETO
The present invention relates to an immunogenic polypeptide, a nucleic acid encoding the same, a pharmaceutical composition comprising the same and the immunogenic polypeptide, nucleic acid or pharmaceutical composition for use as a medicament, particularly a vaccine, or for use in a method of treating or preventing a Borrelia infection.
C07K 14/20 - Peptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés provenant de bactéries provenant de Spirochaetales (O), p. ex. Tréponème, Leptospira
The invention relates to means and methods for preparing aqueous composition comprising aluminium and a protein said composition comprising less than 700 ppm heavy metal on the basis of weight with respect to the aluminium content. The invention further relates to aqueous compositions comprising a protein and an aluminium-salt, said composition comprising less than 350 ppb heavy metal based on the weight of the aqueous composition.
A61K 39/395 - AnticorpsImmunoglobulinesImmunsérum, p. ex. sérum antilymphocitaire
A61K 39/39 - Préparations médicinales contenant des antigènes ou des anticorps caractérisées par les additifs immunostimulants, p. ex. par les adjuvants chimiques
A61K 38/16 - Peptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés
A61K 39/08 - Clostridium, p. ex. Clostridium tetani
C07K 14/33 - Peptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés provenant de bactéries provenant de Clostridium (G)
C07K 16/12 - Immunoglobulines, p. ex. anticorps monoclonaux ou polyclonaux contre du matériel provenant de bactéries
A61K 39/00 - Préparations médicinales contenant des antigènes ou des anticorps
Described herein are improved purification methods for Zika virus vaccines and compositions. Also described are Zika vaccines and methods of producing and administering said Zika vaccines to subjects in need thereof.
C07K 14/20 - Peptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés provenant de bactéries provenant de Spirochaetales (O), p. ex. Tréponème, Leptospira
C07K 14/20 - Peptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés provenant de bactéries provenant de Spirochaetales (O), p. ex. Tréponème, Leptospira
Described herein are methods for administering Opr F antigens to a subject, wherein the subject has a hepatobiliary disorder, a medical history of a hepatobiliary disorder or one or more indicators of a hepatobiliary disorder.
C07K 16/12 - Immunoglobulines, p. ex. anticorps monoclonaux ou polyclonaux contre du matériel provenant de bactéries
C07K 14/21 - Peptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés provenant de bactéries provenant de Pseudomonadaceae (F)
80.
Mutant fragments of OspA and methods and uses relating thereto
C07K 14/20 - Peptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés provenant de bactéries provenant de Spirochaetales (O), p. ex. Tréponème, Leptospira
C07K 16/12 - Immunoglobulines, p. ex. anticorps monoclonaux ou polyclonaux contre du matériel provenant de bactéries
A61K 39/39 - Préparations médicinales contenant des antigènes ou des anticorps caractérisées par les additifs immunostimulants, p. ex. par les adjuvants chimiques
A61K 39/00 - Préparations médicinales contenant des antigènes ou des anticorps
81.
Aluminum compounds for use in therapeutics and vaccines
The invention relates to means and methods for preparing aqueous composition comprising aluminum and a protein said composition comprising less than 700 ppm heavy metal on the basis of weight with respect to the aluminum content. The invention further relates to aqueous compositions comprising a protein and an aluminum-salt, said composition comprising less than 350 ppb heavy metal based on the weight of the aqueous composition.
A61K 39/00 - Préparations médicinales contenant des antigènes ou des anticorps
A61K 39/39 - Préparations médicinales contenant des antigènes ou des anticorps caractérisées par les additifs immunostimulants, p. ex. par les adjuvants chimiques
The invention relates to means and methods for preparing aqueous composition comprising aluminium and a protein said composition comprising less than 700 ppm heavy metal on the basis of weight with respect to the aluminium content. The invention further relates to aqueous compositions comprising a protein and an aluminium-salt, said composition comprising less than 350 ppb heavy metal based on the weight of the aqueous composition.
A61K 39/00 - Préparations médicinales contenant des antigènes ou des anticorps
A61K 39/39 - Préparations médicinales contenant des antigènes ou des anticorps caractérisées par les additifs immunostimulants, p. ex. par les adjuvants chimiques
05 - Produits pharmaceutiques, vétérinaires et hygièniques
42 - Services scientifiques, technologiques et industriels, recherche et conception
44 - Services médicaux, services vétérinaires, soins d'hygiène et de beauté; services d'agriculture, d'horticulture et de sylviculture.
Produits et services
(1) Pharmaceutical and veterinary preparations, namely, vaccines for prevention and treatment of infectious diseases (1) Research and development in the field of therapeutic vaccines and antibiotics against infectious diseases
84.
MUTANT FRAGMENTS OF OSPA AND METHODS AND USES RELATING THERETO
The present invention relates to compositions and methods for the prevention and treatment of Borrelia infection. Particularly, the present invention relates to a polypeptide comprising a hybrid C-terminal fragment of an outer surface protein A (OspA), a nucleic acid coding the same, an antibody specifically binding the same, a pharmaceutical composition (particularly for use as a medicament or in a method of treating or preventing a Borrelia infection) comprising the polypeptide and/or the nucleic acid and/or the antibody, a method of treating or preventing a Borrelia infection and a method of immunizing a subject.
A61K 39/40 - AnticorpsImmunoglobulinesImmunsérum, p. ex. sérum antilymphocitaire bactériens
C07K 14/20 - Peptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés provenant de bactéries provenant de Spirochaetales (O), p. ex. Tréponème, Leptospira
C07K 16/12 - Immunoglobulines, p. ex. anticorps monoclonaux ou polyclonaux contre du matériel provenant de bactéries
The present invention relates to compositions and methods for the prevention and treatment of Borrelia infection. Particularly, the present invention relates to a polypeptide comprising a hybrid C-terminal fragment of an outer surface protein A (OspA), a nucleic acid coding the same, an antibody specifically binding the same, a pharmaceutical composition (particularly for use as a medicament or in a method of treating or preventing a Borrelia infection) comprising the polypeptide and/or the nucleic acid and/or the antibody, a method of treating or preventing a Borrelia infection and a method of immunizing a subject.
C07K 14/20 - Peptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés provenant de bactéries provenant de Spirochaetales (O), p. ex. Tréponème, Leptospira
This invention relates to booster vaccines, i.e. to vaccines that are administered to primed subjects, by using transcutaneous immunization or immunostimulation of biological products, e.g., polypeptides, peptides, and DNA. The inventive schemes are unique and offer several advantages to current applications. Such schemes include those comprising the use of toxoids such as tetanus toxoid (TTx) and/or bacterial antigens such as Escherichia coli heat labile enterotoxin (LT) antigen. The compositions for use according to the invention are not required to be stored at reduced temperatures, but remain stable for extended periods at room temperature, are safe to be used on skin, and are simple to use. Accordingly, the invention is directed, in part, to methods of administration, and the products derived therefrom, comprising a novel application that re-enhances the immune response of the administered composition such as a vaccine to an unexpected high level.
A61K 48/00 - Préparations médicinales contenant du matériel génétique qui est introduit dans des cellules du corps vivant pour traiter des maladies génétiquesThérapie génique
A61K 39/39 - Préparations médicinales contenant des antigènes ou des anticorps caractérisées par les additifs immunostimulants, p. ex. par les adjuvants chimiques
87.
Mutant fragments of OspA and methods and uses relating thereto
A61K 38/00 - Préparations médicinales contenant des peptides
C12N 15/00 - Techniques de mutation ou génie génétiqueADN ou ARN concernant le génie génétique, vecteurs, p. ex. plasmides, ou leur isolement, leur préparation ou leur purificationUtilisation d'hôtes pour ceux-ci
C07K 14/195 - Peptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés provenant de bactéries
C07K 14/20 - Peptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés provenant de bactéries provenant de Spirochaetales (O), p. ex. Tréponème, Leptospira
The present invention relates to a polypeptide comprising a mutant fragment of an outer surface protein A (OspA), a nucleic acid coding the same, a pharmaceutical composition (particularly for use as a medicament of in a method of treating or preventing a Borrelia infection) comprising the polypeptide and/or the nucleic acid, a method of treating or preventing a Borrelia infection and a method of immunizing a subject.
C07K 14/20 - Peptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés provenant de bactéries provenant de Spirochaetales (O), p. ex. Tréponème, Leptospira
C07K 16/12 - Immunoglobulines, p. ex. anticorps monoclonaux ou polyclonaux contre du matériel provenant de bactéries
C12P 21/02 - Préparation de peptides ou de protéines comportant une séquence connue de plusieurs amino-acides, p. ex. glutathion
The present invention relates to a polypeptide comprising a mutant fragment of an outer surface protein A (OspA), a nucleic acid coding the same, a pharmaceutical composition (particularly for use as a medicament of in a method of treating or preventing a Borrelia infection) comprising the polypeptide and/or the nucleic acid, a method of treating or preventing a Borrelia infection and a method of immunizing a subject.
C07K 14/20 - Peptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés provenant de bactéries provenant de Spirochaetales (O), p. ex. Tréponème, Leptospira
C07K 16/12 - Immunoglobulines, p. ex. anticorps monoclonaux ou polyclonaux contre du matériel provenant de bactéries
01 - Produits chimiques destinés à l'industrie, aux sciences ainsi qu'à l'agriculture
05 - Produits pharmaceutiques, vétérinaires et hygièniques
42 - Services scientifiques, technologiques et industriels, recherche et conception
Produits et services
Chemical and/or biological preparations used in industry,
science and agriculture including biotechnological and
biological substances, cells, cell lines, nucleic acids,
recombinant proteins, antigens, blood sera, antibodies and
fragments thereof; biotechnological products for research
and diagnostic uses; viral and biological preparations;
bacterial and viral substances other than for medical and
veterinary uses; chemicals and biological substances for use
in medical science; microorganisms, viruses, viral vectors,
nucleic acids, other than for medical or veterinary
purposes. Pharmaceutical products for human and veterinary uses;
medical preparations; chemical preparations for
pharmaceutical and medical purposes; biotechnological
preparations for medical purposes; proteins, viral
substances, immunological substances, bacterial substances,
enzymatic substances, vaccines and biopharmaceutical
preparations for use in human and veterinary medicine;
diagnostic preparations for use in human and veterinary
medicine; chemical reagents for medical and veterinary
purposes; cell cultures, microorganisms and viruses for
medical and veterinary use; adjuvants used for medical and
veterinary uses; antibiotic substances; vaccines; living
cells and microorganisms as well as viral vectors, proteins,
peptides and nucleic acids or complexes of these molecules
for medical and veterinary purposes; antibodies and
fragments thereof; cells for medical, pharmaceutical and
veterinary uses. Scientific research and development services; research
services in the medical, pharmaceutical and veterinary
field; scientific and industrial research in particular in
the field of biology, molecular biology, cell biology,
biotechnology, bacteriology, immunology, genetics, medicine,
pharmacology, virology, chemistry, scientific research of
vaccines, antibiotics, immunological products for human and
veterinary uses; research and development for novel products
for the developing world; technical consultancy relating to
research in the scientific, medical and veterinary domain;
development and establishment of scientific and industrial
research in particular for the preparation of cells, cell
lines, proteins, viruses, human and animal materials;
development of vaccines; development of medical diagnosis,
therapy and test methods; diagnostic and prognostic analysis
of human, animal, and cellular diseases; diagnostic and
prognostic analysis with the help of cell lines, human and
animal material, microorganisms, molecules; chemical,
medical, pharmaceutical and bacteriological research.
91.
Aluminum compounds for use in therapeutics and vaccines
The invention relates to means and methods for preparing aqueous composition comprising aluminum and a protein said composition comprising less than 700 ppm heavy metal on the basis of weight with respect to the aluminum content. The invention further relates to aqueous compositions comprising a protein and an aluminum-salt, said composition comprising less than 350 ppb heavy metal based on the weight of the aqueous composition.
A61K 39/00 - Préparations médicinales contenant des antigènes ou des anticorps
A61K 39/395 - AnticorpsImmunoglobulinesImmunsérum, p. ex. sérum antilymphocitaire
A61K 39/39 - Préparations médicinales contenant des antigènes ou des anticorps caractérisées par les additifs immunostimulants, p. ex. par les adjuvants chimiques
C07K 16/30 - Immunoglobulines, p. ex. anticorps monoclonaux ou polyclonaux contre du matériel provenant d'animaux ou d'humains contre des récepteurs, des antigènes de surface cellulaire ou des déterminants de surface cellulaire provenant de cellules de tumeurs
A61K 38/16 - Peptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés
C12N 7/00 - Virus, p. ex. bactériophagesCompositions les contenantLeur préparation ou purification
The invention relates to means and methods for preparing aqueous composition comprising aluminium and a protein. The invention further relates to aqueous compositions comprising a protein and an aluminium-salt, said composition comprising less than 350 ppb heavy metal based on the weight of the aqueous composition.
A61K 39/39 - Préparations médicinales contenant des antigènes ou des anticorps caractérisées par les additifs immunostimulants, p. ex. par les adjuvants chimiques
01 - Produits chimiques destinés à l'industrie, aux sciences ainsi qu'à l'agriculture
05 - Produits pharmaceutiques, vétérinaires et hygièniques
42 - Services scientifiques, technologiques et industriels, recherche et conception
Produits et services
Chemical and biological preparations used in industry, science and agriculture, namely, biotechnological and biological substances in the nature of cells, cell lines, nucleic acids, recombinant proteins, antigens, blood sera, antibodies and fragments thereof other than for medical or veterinary use; biotechnological products, namely, diagnostic preparations for research and diagnostic uses; biological viral preparations and biological preparations for use in cell cultures other than for medical or veterinary use; bacterial and viral substances other than for medical and veterinary uses; chemicals and biological chemical preparations for use in medical science, namely, for use in biochemical and clinical research; microorganisms, viruses, viral vectors, [ nucleic acids, ] other than for medical or veterinary purposes Pharmaceutical products for human and veterinary uses for treatment of infectious diseases, autoimmune disorders, cancer, immunological diseases; medical preparations, namely, diagnostic preparations for medical use; chemical preparations for pharmaceutical and medical purposes, namely, infectious diseases, autoimmune disorders, cancer, immunological diseases; biotechnological preparations for medical purposes, namely, medical diagnostic reagents; proteins, viral substances, immunological substances, bacterial substances, enzymatic substances, vaccines and biopharmaceutical preparations for use in human and veterinary medicine for treatment of infectious diseases, autoimmune disorders, cancer, immunological diseases; diagnostic preparations for use in human and veterinary medicine; chemical reagents for medical and veterinary purposes; cell cultures, microorganisms and viruses for medical and veterinary use; adjuvants used for medical and veterinary uses; antibiotic substances; vaccines; living cells and microorganisms as well as viral vectors, proteins, peptides and nucleic acids or complexes of these molecules for medical and veterinary purposes; antibodies and fragments thereof for use in disease testing; cells for medical, pharmaceutical and veterinary uses Scientific research and pharmaceutical development services; scientific research services in the medical, pharmaceutical and veterinary field; scientific and industrial research in particular in the field of biology, molecular biology, cell biology, biotechnology, bacteriology, immunology, [ genetics, ] medicine, pharmacology, virology, chemistry, scientific research of vaccines, [ antibiotics, ] immunological products for human and veterinary uses; research and development for novel products for the developing world; technical consultancy relating to scientific research in the scientific, medical and veterinary domain; scientific research and development and establishment of scientific and industrial research in particular for the preparation of cells, cell lines, proteins, viruses, human and animal materials; development of vaccines; [ development of medical diagnosis techniques, therapy and test methods; ] [ medical and scientific research in the field of diagnostic and prognostic analysis of human, animal, and cellular diseases; medical and scientific research in the field of diagnostic and prognostic analysis with the help of cell lines, human and animal material, microorganisms, molecules; ] chemical, medical, pharmaceutical and bacteriological scientific research
94.
ALUMINIUM COMPOUNDS FOR USE IN THERAPEUTICS AND VACCINES
The invention relates to means and methods for preparing aqueous composition comprising aluminium and a protein. The invention further relates to aqueous compositions comprising a protein and an aluminium-salt, said composition comprising less than 350 ppb heavy metal based on the weight of the aqueous composition.
A61K 39/39 - Préparations médicinales contenant des antigènes ou des anticorps caractérisées par les additifs immunostimulants, p. ex. par les adjuvants chimiques
01 - Produits chimiques destinés à l'industrie, aux sciences ainsi qu'à l'agriculture
05 - Produits pharmaceutiques, vétérinaires et hygièniques
42 - Services scientifiques, technologiques et industriels, recherche et conception
Produits et services
Chemical and/or biological preparations used in industry, science and agriculture including biotechnological and biological substances, cells, cell lines, nucleic acids, recombinant proteins, antigens, blood sera, antibodies and fragments thereof; biotechnological products for research and diagnostic uses; microorganisms; viruses; viral and biological preparations; bacterial and viral substances other than for medical and veterinary uses; chemicals and biological substances for use in medical science; viral vectors; nucleic acids. Pharmaceutical products for human and veterinary uses; medical preparations; chemical preparations for pharmaceutical and medical purposes; biotechnological preparations for medical purposes; proteins, viral substances, immunological substances, bacterial substances, enzymatic substances, vaccines and biopharmaceutical preparations for use in human and veterinary medicine; diagnostic preparations for use in human and veterinary medicine; chemical reagents for medical and veterinary purposes; cell cultures, microorganisms and viruses for medical and veterinary use; adjuvants used for medical and veterinary uses; antibiotic substances; vaccines; viruses; proteins; recombinant proteins; peptides; antigens; peptide antigens; blood sera; antibodies and fragments thereof; cells for medical, pharmaceutical and veterinary uses. Scientific services; research services in the medical, pharmaceutical and veterinary field; scientific and industrial research in particular in the field of biology, molecular biology, cell biology, biotechnology, bacteriology, immunology, genetics, medicine, pharmacology, virology, chemistry, scientific research of vaccines, antibiotics, immunological products for human and veterinary uses; research and development for novel products for the developing world; evaluation, estimation, research in the scientific, medical and veterinary domain; development and establishment of scientific and industrial research in particular for the preparation of cells, cell lines, proteins, viruses, human and animal materials; development of vaccines; development of medical diagnosis, therapy and test methods; diagnostic and prognostic analysis of human, animal, and cellular diseases; diagnostic and prognostic analysis with the help of cell lines, human and animal material, microorganisms, molecules; chemical, medical, pharmaceutical and bacteriological research.
96.
NOVEL OPRF/I FUSION PROTEINS, THEIR PREPARATION AND USE
The present invention relates to a novel trimeric OprF/I fusion protein comprising a portion of the Pseudomonas aeruginosa outer membrane protein F which is fused with its carboxy terminal end to a portion of the amino terminal end of the Pseudomonas aeruginosa out membrane protein I, wherein said portion of the Pseudomonas aeruginosa outer membrane protein F comprises the amino acids 190-342 of SEQ ID NO: 1 and wherein said portion of the Pseudomonas aeruginosa outer membrane protein I comprises the amino acids 21-83 of SEQ ID NO: 2, and further to a novel Opr F/I fusion protein which contains a disulphide bond pattern, preferably selected from the group consisting of (a) Cys18-Cys27-bond, (b) Cys18-Cys27-bond and Cys33-Cys47-bond, and (c) Cys18-Cys47 and Cys27-Cys33-bond, and to immunogenic variants thereof having at least 85% identity to the amino acid sequence of SEQ ID NO: 3. The present invention also relates to a novel method for producing said OprF/I fusion proteins and to their use for the preparation of a pharmaceutical composition and for the preparation of antibodies or antibody derivatives which specifically bind said novel OprF/I fusion proteins.
C07K 14/21 - Peptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés provenant de bactéries provenant de Pseudomonadaceae (F)
This present invention provides C-TAB.G5 and C-TAB.G5.1 isolated polypeptides comprising the receptor binding domains of C. difficile toxin A and toxin B as set forth in the amino acid sequences of SEQ ID NO: 2 and SEQ ID NO: 4. The C-TAB.G5 and C-TAB.G5.1 isolated polypeptides may be used to neutralize toxic effects of C. difficile toxin A and/or toxin B.
A61K 39/08 - Clostridium, p. ex. Clostridium tetani
C07K 14/33 - Peptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés provenant de bactéries provenant de Clostridium (G)
98.
ISOLATED POLYPEPTIDE OF THE TOXIN A AND TOXIN B PROTEINS OF C. DIFFICILE AND USES THEREOF
This present invention provides C-TAB.G5 and C-TAB.G5.1 isolated polypeptides comprising the receptor binding domains of C. difficile toxin A and toxin B as set forth in the amino acid sequences of SEQ ID NO: 2 and SEQ ID NO: 4. The C-TAB.G5 and C-TAB.G5.1 isolated polypeptides may be used to neutralize toxic effects of C. difficile toxin A and/or toxin B.
A61K 39/08 - Clostridium, p. ex. Clostridium tetani
C07K 14/33 - Peptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés provenant de bactéries provenant de Clostridium (G)
